Objectives:The aim of this study is to asses prevalence & clinical outcome of hyperparathyroidism among CKDpatients either on dialysis or not in Sohag University Hospital 1.To estimate serum intact parathormone(iPTH) and other biochemical parameters (calcium, inorganic phosphate, urea and creatinine)in CKDpatients2. To compare and find out correlation between serum intact parathormone and biochemicalparameters in the study group. Patients &Methods: For the study of 5 stages of Chronic Kidney Disease(CKD) totally 100 patients in different stages inthe age group of 20-60 years were taken. Serum parathormone and other biochemical parameters were estimated using standard methods.Pelvi-abdominal ultrasonography,Plain x-ray,ECG & Echocardiography were also done. Results:66 patients (66.00%) with PTH values above the normal range (hyperparathyroidism) (>72 pg/ml), with mean PTH = 481.92 ± 608.05, and this is the prevalence rate of secondary hyperparathyroidism in the study population. The serum PTH levels were higher even in early stages of CKD and the higher values are directly related to the stage of CKD. In the study, Serum phosphorus was found to be significantly positively correlated to PTH both in the total study population and in patients with hyperparathyroidism.The PTH was found to be significantly negatively correlated with serum total and ionized calcium of the patients, both in the total study population and in patients with hyperparathyroidism.Also the findings of this study as regard echocardiography in CKD patients;Left ventricular dysfunction was the commonest cardiovascular abnormality. LVH was the most common echocardiographic abnormality in CKD cases. Diastolic function was deranged in more number of patients as compared to systolic function in patients with CKD. Conclusion: The estimation of serum PTH and other biochemical parameters can help to diagnose the secondary hyperparathyroidism in the early stage of CKD which inturn has advantage to manage the patients of CKD accordingly to prevent the future complications.
Introduction
Today CKD is a major health concern affecting 5-10% of the population globally 1 . The global incidence and prevalence of CKD is growing, mainly attributed to the ageing population and the concomitant increase in CKD risk factors, such as hypertension and diabetes. The age-adjusted mortality risk is increased already in early stages of CKD and increases further as the deterioration in renal function progresses 2 . In patients with CKD stage 5, also called end stage renal disease (ESRD), the five-year survival rate is approximately 50%
3 . Secondary hyperparathyroidism is a common complication of chronic kidney disease (CKD), and is characterized by elevated levels of serum parathyroid hormone (PTH) and abnormalities in bone and mineral metabolism 4 .
The mechanisms by which the decrease in plasma calcium and vitamin D (calcitriol) and the increase in plasma phosphate in advanced stages of chronic renal failure stimulate PTH secretion became more obvious during the last decade 6 . These disturbances, in addition to several long known indirect effects, they all have also been shown to act directly on the parathyroid cell, via a cell membrane receptor for calcium 7 , a nuclear receptor for calcitriol 8 , and a yet unknown cellular target for phosphate 9 . In chronic renal failure, secondary hyperparathyroidism is associated with significant clinical risks, including risks for renal bone disease, cardiovascular and death, as well as less frequently recognized neurotoxicities and endocrinopathies 10 . The bone, as one of the main organs for handling calcium and phosphate, is dependent on a well-regulated mineral metabolism to maintain its normal function, and as a consequence bone abnormalities are frequently found in the CKD population. The alterations in bone morphology associated with CKD are termed renal osteodystrophy, and encompasses changes in bone turnover, mineralization and bone volume. Renal osteodystrophy may result in fractures, bone pain and impaired linear growth inchildren 11 . In parallel with bone abnormalities there is an increase in extraosseous calcifications in CKD, most importantly in the vasculature. Vascular calcification develops as a result of an imbalance between inducers and inhibitors of the calcification process, and several known inhibitors, including Fetuin-A and matrix Gla-protein, are reduced in CKD patients 12 .
Accordingly, vascular calcification is a major concern in CKD patients with increased prevalence already at CKD stage 3 (40% compared to 13% in healthy individuals), and is a universal phenomenon in ESRD (approximately 80%). Vascular calcification is closely related to and considered to be a valid surrogate for the longitudinal risk of CVD and mortality 13 . Although the molecular mechanism behind vascular calcification is not fully elucidated it appears to be a combination of passive deposition and an active cellular process. The passive deposition is caused by precipitation of high circulating concentrations of calcium and phosphate into the vascular wall, while the active process is commonly viewed as a dedifferentiation of vascular cells into bone-like cells, triggered by various stimuli 14 .
Patients and Methods
The aim of this study is to asses prevalence & clinical outcome of hyperparathyroidism among CKDpatients either on dialysis or not in Sohag University Hospital. This study was done in the nephrology clinic and the hemodialysis unit at Sohag University Hospital. It was conducted on 100 patients with CKD, either on regular hemodialysis or not.
The following patients will be excluded from the study:
• Patients with primary parathyroid gland disease or malignancy.
• Patients with known bone disease or malignancy.
• Postmenopausal women.
• Elderly patients above 60 years old.
• Patients on phenytoin, steroids or phenobarbitone as they affect bone biochemical factors. All patients involved in the study were subjected to the following: A) Careful medical history:
• Personal history.
• Present history including the original kidney disease, time on dialysis (in months), any cardiovascular, chest disease, diabetic status....
B) Full clinical examination:
• Careful general examination including heart, chest, abdominal and neurological examination C) Laboratory investigations: Which included:
• Urine analysis.
• Blood urea and serum creatinine level ( will be done before and after dialysis in patients on hemodialysis)
• Estimated GFR to determine the stage of CKD • Serum ionized calcium (ca) and phosphorus (ph) levels.
• Serum iPTH level.
• Serum Alkaline phosphatase (Alp).
• Serum albumin (Alb).
• Random blood sugar.
• Hemoglobin (Hb) level and hematocrit (Hct) value.
• Neck ultrasound and parathyroid scan will be done to patients with suspected tertiary hyperparathyroidism to confirm the diagnosis D)Pelvi-abdominal ultrasonography: E) Plain x-ray: to detect calcifications in the vessels. F) ECG & Echocardiography: G) Densometer: to detect bone density.
Results
Our study included 100 patients with CKD either on dialysis or not randomly selected from Dialysis Unit and Nephrology Clinic in Sohag University Hospital. Table 1 shows that, the mean age of the patients was 44.13 ±9.78 years (ranged from 18-59 years), 63 males (63 %) and 37 females (37 %) were included, and they were on different stages of CKD each stage from stage1 to 4 included 10 (10.00%) patients and stage 5 included 60 (60.00%) patients who were on haemodialysis treatment for duration for 6.58 ± 3.09 years. 31 patients (31.00%) were diabetic who were on oral hypoglycemic treatment 13 patients and on insulin therapy 18 patients and 33 patients (33.00%) have history of hypertension . 3 patients (3.00%) were previously diagnosed to have IHD.
Mahmoud Kh. Mahmoud 370 
28.98±15.85 24 (9-103)
The echocardiographic manifestations were LVH was observed in 51 (51.00%) patients, diastolic dysfunction (DD) as expressed by E/A ratio was present in 53 (53.00%) patients, dilated left atrium was present in 19 (19.00%) patients, dilated right side was present in 5 (5.00%) patients. Mean LVEDD (left ventricular end diastolic diameter) was 4.90±0.97cm, mean EF (ejection fraction) was 59.92±6.93 (Table. 3). Other echocardiographic manifestations like IHD expressed as regular wall motion abnormality (hypokinesia) was observed in 17 (17.00%) patients, pericardial Effusion was present in 14 (14.00%) patients, and valvular calcification was present in 5 (5.00%) patients (Table 4) . There was significant positive correlation between three groups of study population and serum PTH levels p value = 0.0001 and correlation between each two groups and serum PTH levels p 1 = 0.1, p 2 = 0.0001, p 3 = 0.0001 (Table 7) . Also, there was positive significant correlation between three groups and serum Po 4 p value = 0.0001 and correlation between each two groups and serum Po 4 levels p 1 = 0.01, p 2 < 0.0001, but no significant correlation between severe CKD and stage 5 p 3 = 0.85 (Table 7) . While, there was negative significant correlation between three groups and serum total and ionized calcium p value = 0.01, p value = 0.001 respectively and correlation between each two groups and serum total and ionized calcium levels p 1 = 0.02 p 1 = 0.001 respectively, p 2 = 0.02 p 2 = 0.0009 respectively, but also no significant correlation between severe CKD (stage 3-4) and stage 5 p 3 = 1.00 p 3 = 0.63 respectively (Table 7) . When we compared three groups of CKD patients to Echocardiographic findings, we found significant correlation between CKD stages and LVH p value < 0.0001 and correlation between each two groups and LVH p 1 value = 0.08 and p 2 value < 0.0001, and p 3 value = 0.04 (Table 9) . Our results found correlation between stages CKD patients and EF with p value = 0.03 (Table 9) , and LVEDd with p value = 0.01 (Table 16 ). Also, there was significant correlation between CKD stages in diastolic dysfunction (DD) that was denoted by E/A ratio p value < 0.0001, p 1 value = 0.003, p 2 value < 0.0001, and p 3 value = 0.03 (Table16). Table 10 showed significant correlation between different stages of CKD patients and RWMA (hypokinesia) i.e. ischemia with p value = 0.001, but no significant correlation between different stages of CKD predialysis patients p 1 value = 1.00, while there was significant correlation between each stage CKD predialysis patients (stage 1-2, and stage 3-4) and CKD (stage 5) dialysis patients p 2 value = 0.005, and p 3 value = 0.005 (Table  10) .
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DISCUSSION
Secondary hyperparathyroidism is a common complication of chronic kidney disease (CKD), and is characterized by elevated levels of serum parathyroid hormone (PTH) and abnormalities in bone and mineral metabolism. 4 This serious disorder arises from disturbances in the regulation of the intracellular and extracellular levels of PTH, calcium, phosphorus, and vitamin D (calcitriol), which become more severe as kidney function declines and the interaction between these factors is complex, and effective control of secondary HPT can create a significant challenge.
15
This study was conducted on 100 patients with different stages of chronic kidney disease in Sohag University Hospital. The reference range for serum PTH was 12-72 pg/ml. 66 patients have PTH above 72 pg/ml, this means that the prevalence of secondary hyperparathyroidism in our study is 66.00%, with mean PTH = 481.92 ± 608.05. This prevalence is in agreement with MalawadiBn et al in 2014, who studied the prevalence of secondary hyperparathyroidism in 150 patients with chronic kidney disease different stages.Although this prevalence lower than that that was estimated by 138 who reported 36% incidence, and this is explained by decreased number of stages of CKD predialysis patients in their studies(8% in Goornavar et al) , but our study included 40% of all study populations, and In the present study statistically significant correlation was observed between left ventricular hypertrophy and stage of the chronic kidney disease (p-value < 0.0001) and duration of dialysis (p-value = 0.001). In the present study ischemic heart disease was documented in 17(17.00%) patients echo, in consistent with Goornovar et al who reported 16% incidence of ischemic heart disease, but in contrast to Parfrey et al Pericardial effusion was reported in 14 (14.00%) patients which is consistent with a study by Laddha M et al 2014 where they found 14.3% patients with pericardial effusion, and Shvendra et al who reported an incidence of 17.14%, but is not consistent with Goornvar et al who reported incidence of 6% patients and Barrionuevo JDA et al (2010) et al where they found 6.5% patients with pericardial effusion, While Menon et al (1998) who reported 32 % incidence and Achari et al (1989) who reported 50% incidence of pericardial effusion in chronic kidney disease patients, this is due to this study included CKD patients with different stages but most of other studies included CKD patients on dialysis, also hypervolemia and insufficient dialysis are co-factors affect in the results. Diastolic dysfunction as denoted by E/A ratio was present in 53(53.00%) of patients, which is consistent with Laddha M et al 2014 who reported an incidence 61.4% of patients with diastolic dysfunction. Valvular calcification was noted in 5% of CKD patients, which is consistent with Laddha M et al 2014 who reported an incidence 7.1% of patients.
Conclusion
We can conclude that the prevalence of secondary hyperparathyroidism in chronic kidney disease is high In our study ( 
